Skip to playerSkip to main content
Benzinga
  • 2 years ago
Pfizer's second-quarter revenue and adjusted earnings per share both exceeded analyst estimates, showing a growth from the previous year. Pfizer raised its full-year revenue and adjusted EPS guidance, reflecting increased expectations from earlier projections. Sales of the company's COVID antiviral pill, Paxlovid, increased year over year, beating estimates. Demand has increased in international markets. The company is focusing on cancer treatments following its acquisition of Seagen last year.
Transcript
00:00It's Benzinga, and here's what's on the block.
00:02Pfizer's second quarter revenue and adjusted earnings per share both exceeded analysts'
00:06estimates showing a growth from the previous year.
00:09Pfizer raised its full-year revenue and adjusted EPS guidance reflecting increased expectations
00:15from earlier projections.
00:17Sales of the company's COVID antiviral pill Paxlovid increased year-over-year, beating
00:21estimates.
00:22Demand has increased in international markets.
00:25The company is focusing on cancer treatments following its acquisition of CGen last year.
00:29To see all things money, visit Benzinga.com.